๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Gastroesophageal-junction Cancer
Clinical trial register · China

Gastroesophageal-junction Cancer Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 6 Chengdu 4 Shanghai 4 Hangzhou 3 Wuhan 2
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing6 Chengdu4 Shanghai4 Hangzhou3 Wuhan2
All 20 locations
Target enrolment
to

Gastroesophageal-junction Cancer trials in China

13 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
NCT07392892Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
Pfizer
Phase 2/3
840
Shanghai
2026-05-14
Not yet open
Non-Invasive Detection of claudin18.2 in Pancreatic and Gastric/Gastroesophageal Junction Cancer by [68Ga]Ga-NODAGA-SNA014 PET Imaging
NCT07554742Pancreatic Cancer, Gastric Cancer, Gastroesophageal Junction Cancer
Ruijin Hospital
Observational
64
Shanghai
2026-04-15
Recruiting
Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
NCT07315854Gastric Cancer (GC), Gastroesophageal Junction Cancer, Advanced Gastric Cancer, Metastatic Gastric Cancer
Beijing Friendship Hospital
Phase 2
32
Beijing
2025-11-04
Recruiting
A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer
NCT07110571Gastric Cancer, Gastroesophageal-junction Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2
200
Shijiazhuang, Hangzhou
2025-08-28
Active, closed
Study for AZD4360 in Participants With Advanced Solid Tumours
NCT06921928Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
AstraZeneca
Phase 1/2
31
Beijing, Chengdu, Shanghai, Wuhan
2025-04-29
Recruiting
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478Gastric Cancer, Gastroesophageal Junction Cancer
Daiichi Sankyo
Phase 3
726
Beijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou
2025-02-27
Recruiting
A Phase โ…ข Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
NCT06532006Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer
Shanghai Henlius Biotech
Phase 3
550
Baise City, Beijing, Bengbu, Changchun, Changsha, Changzhi, Changzhou, Chengdu
2024-11-22
Active, closed
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
NCT06346392Gastric Cancer, Gastroesophageal Junction Cancer
AstraZeneca
Phase 3
594
Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei
2024-03-04
Recruiting
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
NCT06219941Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
AstraZeneca
Phase 2
226
Changsha, Chengdu
2023-12-13
Recruiting
Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
NCT05687357Gastric Cancer, Gastroesophageal-junction Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
140
Wuhan, Nanjing, Taiyuan
2023-03-15
Recruiting
Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
NCT06121700Adenocarcinoma, Stomach Neoplasm, Gastroesophageal-junction Cancer, Oligometastatic Disease
Fudan University
Phase 2
55
Shanghai
2023-01-01
Recruiting
XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma
NCT05494060Carcinoma, Gastrointestinal Diseases, Stomach Cancer, Gastroesophageal-junction Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2
80
Nanjing
2022-03-16
Active, closed
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
NCT04931654Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer
AstraZeneca
Phase 1/2
136
Beijing, Guangzhou
2021-09-28
Rows per page Showing 1–13 of 13
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/gastroesophageal-junction-cancer

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 13 of those studies listing the condition Gastroesophageal-junction Cancer.

How many Gastroesophageal-junction Cancer trials are recruiting in China?

9 of the 13 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Gastroesophageal-junction Cancer), 13 studies
PhaseStudiesRecruitingShare
Phase 26646.2%
Phase 33223.1%
Phase 1/22015.4%
Observational107.7%
Phase 2/3117.7%

Most active sponsors

Lead sponsors with the most studies (Gastroesophageal-junction Cancer)
Lead sponsorStudiesRecruiting
AstraZeneca41
Beijing Friendship Hospital11
Daiichi Sankyo11
Fudan University11
Pfizer11
Ruijin Hospital10
Shanghai Henlius Biotech11
Suzhou Suncadia Biopharmaceuticals Co., Ltd.11
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School11
The First Affiliated Hospital with Nanjing Medical University11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.